References
- Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995;74:167–71
- Verstaete M, Vermylen J, Donati MB. The effect of streptokinase infusion on chronic arterial occlusions and stenoses. Ann Int Med 1971;74:377–82
- Lizano S, Kenneth HJ. Structural diversity of streptokinase and activation of human plasminogen. Infect Immun 2005;73:4451–3
- Wakeham N, Terzyan S, Zhai P, et al. Effects of deletion of streptokinase residues 48–59 on plasminogen activation. Protein Eng 2002;15:753–61
- Tharp AC, Laha M, Panizzi P, et al. Plasminogen substrate recognition by the streptokinase-plasminogen catalytic complex is facilitated by Arg253, Lys256, and Lys257 in the streptokinase domain and Kringle 5 of the substrate. J Biol Chem 2009;284:19511–21
- Banerjee A, Chisti Y, Banerjee UC. Streptokinase-a clinically useful thrombolytic agent. Biotech Adv 2004;22:287–307
- Saito H, Goldsmith GH, Moroi M, Aoki N. Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc Natl Acad Sci USA 1979;76:2013–17
- Reed GL, YAN KA, Lin Liu H, et al. A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. Proc Natl Acad Sci USA 1999;96:8879–83
- Rimon A, Shamash Y, Shapiro B. The plasmin inhibitor of human plasma. J Biol Chem 1966;241:5102–7
- Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn 1981;17:1247–8
- Derechin M. The assay of human plasminogen with casein as substrate. Biochem J 1961;78:443–8
- Cederholm-Williams SA. Concentration of plasminogen and antiplasmin in plasma and serum. J Clin Pathol 1981;34:979–81